Will DOW report Q1 2026 operating EBITDA of at least $1.0B?

Management explicitly guided Q1 2026 to approximately $750M — a step of only ~$9M from Q4 2025 $741M. Hitting $1.0B requires a 33% beat against a flat guidance baseline. Roadkill Radar converged on OPERATIONAL_EXECUTION = MEETING (lower-end), explicitly not ACCELERATING. Companies typically deliver within +/-10% of near-term guide; a 33% beat is a tail event. China VAT rebate benefit and T2O incremental savings are real but unlikely to collectively deliver $250M in a single quarter above guide. Probability meaningfully below 30%.

Outgoing CEO Fitterling has incentive to set conservative exit guidance so Carter inherits achievable bar. That provides modest upside bias. However, $1.0B quarterly EBITDA implies $4B annualized run-rate which is 23% above FY25 $3.26B — this is cycle-recovery territory, not cycle-trough baseline. Q4 was flat. Q1 2026 working capital likely reverses some of FY25 $1.5B inventory benefit. Feedstock / raw materials moderate but not obviously favorable. I see $750-850M as base case, $850-950M as bull case, $1B+ as tail.

Moat Mapper's structural erosion signal is important here. If cycle-peak EBITDA compression continues ($8-10B -> $6.5-7B -> projected $5-6B), Q1 2026 at $1B+ would imply the new 'cycle peak' is arriving — inconsistent with the committee's Q1 recovery framing which expects EBITDA to build through 2026-2027. A $1B Q1 print would be positively surprising on magnitude and would suggest structural framing is wrong; base rates for this kind of inflection in a single quarter are low. 15-20% probability.

Company guided $750M for Q1. Beats to guidance in chemicals cycle-trough quarters are typically 5-15%. A 33% beat requires external positive shock (commodity spike, unexpected price/mix benefit, T2O overachievement). China VAT rebate elimination is a real tailwind but incremental, not step-change. Probability of $1B+ print: ~20%.

Cycle trough quarters can show abrupt inflections when multiple tailwinds align. FY25 restructuring completion means FY26 base has lower SG&A; T2O has been delivering; European rationalization is starting to take effect. If Q1 2026 catches favorable tailwinds (feedstock timing, polyethylene pricing recovery, Sadara losses moderating), $900M-$1B is within reach. I place probability at 25% because the model under-weights the cumulative impact of restructuring completion.

Myth Meter's DEMANDING classification implies the market is already partly pricing Q1 modest beat (~$800-900M). Management underselling guide to $750M is a classic beat-setup. But $1B is a round-number narrative threshold that would drive outsized stock reaction — exactly why company wouldn't guide to it. Typical conservative-guide firms beat by 10-20%, putting most-likely outcome at $825-$900M. Probability of $1B+: ~20%.

Guide $750M, need $1B (33% beat). Unusual magnitude for a single quarter. T2O and China VAT rebate provide tailwinds but insufficient to bridge gap alone. Most likely outcome is modest beat to $800-900M. ~20-25% probability of $1B+.

Guidance is $750M with cycle-trough fundamentals. $1B represents 23% annualized EBITDA recovery from FY25 in Q1 alone — aggressive. Not impossible given restructuring + T2O but probability lower than base case.

Company guidance is the strongest anchor. $750M guide + historical beat patterns of 10-20% implies most-likely print of $800-900M. $1B requires significantly above-trend beat. Probability around 20%.